Atea Pharmaceuticals, Inc.

NasdaqGS:AVIR Stock Report

Market Cap: US$269.4m

Atea Pharmaceuticals Future Growth

Future criteria checks 0/6

Atea Pharmaceuticals is forecast to grow earnings and revenue by 3.2% and 165.5% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be -61.1% in 3 years.

Key information

3.2%

Earnings growth rate

15.5%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate165.5%
Future return on equity-61.1%
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

Atea wins FDA Fast Track status for dengue treatment

Sep 26

Atea Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

May 13
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15
Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13
Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08
Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06
Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30
Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Earnings and Revenue Growth Forecasts

NasdaqGS:AVIR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202612-163-163-1382
12/31/2025N/A-156-174-1492
12/31/2024N/A-169-97-712
9/30/2024N/A-174-127-127N/A
6/30/2024N/A-176-121-121N/A
3/31/2024N/A-164-95-95N/A
12/31/2023N/A-136-85-85N/A
9/30/2023N/A-131-85-85N/A
6/30/2023N/A-106-89-89N/A
3/31/2023N/A-109-94-92N/A
12/31/2022N/A-116-123-121N/A
9/30/202219236-177-175N/A
6/30/202222516-133-131N/A
3/31/202228548-129-129N/A
12/31/2021351121-87-87N/A
9/30/202120825307307N/A
6/30/202117535275275N/A
3/31/202111524284284N/A
12/31/202049-11297297N/A
9/30/2020N/A-36-26-26N/A
6/30/2020N/A-22-20-20N/A
3/31/2020N/A-16-14-14N/A
12/31/2019N/A-14-13-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVIR is forecast to have no revenue next year.

High Growth Revenue: AVIR is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AVIR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atea Pharmaceuticals, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric JosephJ.P. Morgan
Roanna Clarissa RuizLeerink Partners LLC
Matthew HarrisonMorgan Stanley